产品说明书

Bifendate

Print
Chemical Structure| 73536-69-3 同义名 : DDB
CAS号 : 73536-69-3
货号 : A100986
分子式 : C20H18O10
纯度 : 99+%
分子量 : 418.351
MDL号 : MFCD01751431
存储条件：

粉末 Keep in dark place,Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 12 mg/mL(28.68 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Bifendate (DDB) is a synthetic intermediate of Schisandrin C with anti-HBV efficacy in research of chronic hepatitis BCui S, Wang M, Fan G. [Anti-HBV efficacy of bifendate in treatment of chronic hepatitis B, a primary study. Zhonghua Yi Xue Za Zhi. 2002;82(8):538-540. |https://pubmed.ncbi.nlm.nih.gov/12133500/]}. Administration of the usual therapeutic dose of bifendate decreased the plasma concentration of cyclosporine in all subjects, which was companied by a marked decrease in the peak plasma concentration{{Zeng Y, He YJ, He FY, Fan L, Zhou HH. Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects. Acta Pharmacol Sin. 2009 Apr;30(4):478-84. |https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002280/. Daily administration of bifendate (0.03-1,0g/kg, i.g.) for 4 days decreased hepatic level of total cholesterol and triglyceride in hypercholesterolemic mice, and supplementing the high-fat diet mice with bifendate caused more significant decreases in hepatic total cholesterol and triglyceride levels (25-56%, and 22-24% respectively)[1].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.39mL

0.48mL

0.24mL

11.95mL

2.39mL

1.20mL

23.90mL

4.78mL

2.39mL
参考文献

[1]Pan SY, Yang R, Dong H, Yu ZL, Ko KM. Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Eur J Pharmacol. 2006;552(1-3):170-175.